Clinical trials: Metastatic Solid Cancers
Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic)
Immune Cell Therapy for Advanced Solid Tumors
The autologous immune cell induction technology used in this project involves transforming peripheral blood mononuclear cells (PBMC) into autologous DC cells, NK cells, CIK cells and other immune cells through cytokine induction…
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic), Colorectal Cancer (Locally Advanced or Metastatic), Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07260058
- Testing
- Autologous immune Cells, Standard chemotherapy
- Volunteers
- 48 people
- Sponsor
- Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
Advanced Cancer, Metastatic Solid Tumor
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
The main objective for part 1a of the study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of oral TACH101…
- Conditions
- Advanced Cancer, Metastatic Solid Tumor, Solid Tumor
- Trial name
- NCT05076552
- Testing
- TACH101
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tachyon Therapeutics, Inc.
Advanced/Metastatic Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX48 in patients with advanced/metastatic solid tumors.
- Trial name
- NCT07473726
- Testing
- HLX48
- Where
- 7 sites in Australia, China
- Volunteers
- 72 people
- Sponsor
- Shanghai Henlius Biotech
Solid Tumors, Ovarian Cancer
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors
- Conditions
- Solid Tumors, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT02476955
- Testing
- ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Metastatic Pancreatic Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic…
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Trial name
- NCT03261947
- Testing
- TAK-931
- Where
- 10 sites in United States, Japan
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy
- Trial name
- NCT04430933
- Testing
- NC318, Pemetrexed/Carboplatin, Nab paclitaxel/Carboplatin
- Sponsor
- NextCure, Inc.
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
- Trial name
- NCT06835569
- Testing
- ALTA3263, cetuximab, mFOLFOX6
- Where
- 14 sites in United States
- Volunteers
- 448 people
- Sponsor
- Alterome Therapeutics, Inc.
Metastatic Solid Tumor, Advanced Solid Tumor
Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is an open-label, Phase 1, multicenter, continuous dose escalation study of XT-0528 in adult subjects with Advanced or Metastatic Solid Tumor Malignancies.
- Trial name
- NCT05474859
- Testing
- XT-0528
- Volunteers
- 30 people
- Sponsor
- Xenthera, Inc.
Advanced or Metastatic Solid Tumours
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK127 in combination with AK104.
- Trial name
- NCT05021120
- Testing
- AK127, AK104
- Where
- 5 sites in Australia
- Volunteers
- 67 people
- Sponsor
- Akesobio Australia Pty Ltd
Cancer
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
This Phase II study is conducted to assess the safety and efficacy of CPI-613 in patients with advanced and/or metastatic solid tumors for whom there there is no available therapy to provide clinical benefit or for those who have…
- Trial name
- NCT01832857
- Testing
- CPI-613
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Cornerstone Pharmaceuticals
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
Solid Tumors
Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of ATB-320 in patients with progressive or metastatic solid tumors
- Trial name
- ATB-320-001A (NCT06933524)
- Testing
- ATB-320
- Volunteers
- 24 people
- Sponsor
- Autotelicbio
Colorectal Neoplasms, Hepatocellular Carcinoma
Dendritic Killer Cell-based Immunotherapy for Solid Tumors
The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC.
- Conditions
- Colorectal Neoplasms, Hepatocellular Carcinoma, Neoplasm Metastasis
- Trial name
- NCT02882659
- Testing
- Dendritic Killer Cell (DKC)
- Volunteers
- 18 people
- Sponsor
- FullHope Biomedical Co., Ltd.
Uterine Neoplasms, Uterine Cervical Neoplasms
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the…
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
- Trial name
- NCT04579380
- Testing
- tucatinib, trastuzumab, fulvestrant
- Where
- 108 sites in United States, Belgium and 6 more
- Volunteers
- 217 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Neoplasm
Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)
A clinical study evaluates the safety, tolerability, and pharmacokinetics of ridaforolimus (MK-8669) in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT00694083
- Testing
- Ridaforolimus
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Advanced or Metastatic Solid Tumors
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly (QW) and twice daily-once weekly (BID-QW).
- Trial name
- HERKULES-1 (NCT04866134)
- Testing
- ERAS-007, ERAS-601
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Erasca, Inc.
Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either…
- Trial name
- NCT04485013
- Testing
- TTX-080, pembrolizumab, cetuximab
- Where
- 41 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tizona Therapeutics, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.